drugset / Trial / NCT02459418

Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application

NCT02459418

Phase 1 Completed 42 enrolled Fertility Biotech AG
RandomizedCrossoverOpen-labelOther

Summary

Comparative PK study after single SC application of Afolia and the reference product (US Gonal-f®). Objective: To demonstrate equivalence within 80%-125% margin of the reference product for the area under the curve (AUC) of Afolia.

Timeline

Start
2015-05-07
Primary completion
2016-05-19
Completion
2016-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Gonal-f Protein / enzyme biologic 225 iu Subcutaneous

Indications

No indication recorded.